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The effect of different food matrices on the metabolism and excretion of polyphenols is uncertain. The objective of the study was to evaluate the
possible effect of milk on the excretion of (2)-epicatechin metabolites from cocoa powder after its ingestion with and without milk. Twenty-one
volunteers received the following three test meals each in a randomised cross–over design with a 1-week interval between meals: (1) 250 ml whole
milk as a control; (2) 40 g cocoa powder dissolved in 250 ml whole milk (CC–M); (3) 40 g cocoa powder dissolved in 250 ml water (CC–W).
Urine was collected before consumption and during the 0–6, 6–12 and 12–24 h periods after consumption. (2 )-Epicatechin metabolite excretion
was measured using liquid chromatography–MS. One (2)-epicatechin glucuronide and three (2 )-epicatechin sulfates were detected in urine
excreted after the intake of the two cocoa beverages (CC–M and CC–W). The results show that milk does not significantly affect the total
amount of metabolites excreted in urine. However, differences in metabolite excretion profiles were observed; there were changes in the glucur-
onide and sulfate excretion rates, and the sulfation position between the period of excretion and the matrix. The matrix in which polyphenols are
consumed can affect their metabolism and excretion, and this may affect their biological activity. Thus, more studies are needed to evaluate the
effect of these different metabolite profiles on the body.
(2 )-Epicatechin metabolites: Cocoa powder: Flavonoids: Urine: Glucuronide: Sulfate excretion
The bioavailability of flavonoids (considering intestinal
absorption, metabolic conversion and urinary excretion) is
an important factor when evaluating their in vivo activity
and possible beneficial effects after intake(1 – 3). Flavonoids
are generally consumed in food together with other macronu-
trients, micronutrients and other components. Various studies
have shown that some dietary components enhance polyphe-
nol absorption(4 – 7) although others report reduction and null
effect of some foods on their bioavailability(8 – 10). However,
few studies have evaluated the influence of food on flavonoid
phase II metabolism and flavonoid metabolite excretion profile
in urine for humans(2).
During the course of absorption, polyphenols are conjugated
in the small intestine and later in the liver, the primary site of
drug metabolism in the body(11). Typically, metabolic conver-
sion of a drug results in inactivation, detoxification and an
enhanced likelihood of excretion in urine or faeces. Sulfation,
glucuronidation and glutathione conjugation represent the three
most prevalent classes of phase II metabolism. In addition,
these three conjugation reactions increase the molecular
weight and water solubility of the compound. As a result the
phase II conjugates tend to have very poor membrane
permeability and need carrier-mediated transport for biliary
or hepatic basolateral excretion into sinusoidal blood for
eventual excretion via urine. The conjugation mechanisms
are highly efficient, and generally aglycones are either
absent in the blood or only present in low concentrations
after the consumption of nutritional doses(1,12 – 14).
Sulfotransferases catalyse the transfer of a sulfate moiety
from 30-phosphoadenosine-50-phosphosulfate to a hydroxyl
group on polyphenols, although neither the isoforms that
are specifically involved in the conjugation nor the positions
of sulfation for polyphenols have been clearly identified
yet, but sulfation clearly occurs mainly in the liver(1,11).
Glucuronidation is a biosynthetic reaction in which a suitable
functional group on the acceptor molecule (substrate or
aglycone) is conjugated with glucuronic acid (GA). This
reaction (which requires uridine 50-diphospho (UDP)-GA as
a co-substrate) is catalysed by the enzyme UDP-glucoronosyl-
tranferase. Conjugation with GA is responsible for the deacti-
vation and elimination of a wide range of xenobiotics and
endogenous compounds(1,11,15). UDP-glucoronosyltranferases
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are membrane-bound enzymes that are located in the
endoplasmic reticulum in many tissues and that catalyse the
transformation of a GA from UDP-GA to polyphenols, and
thousands of dietary constituents and xenobiotics. The pre-
sence of glucuronidated metabolites in the mesenteric or
portal blood after perfusion of polyphenols in the small intes-
tine of rats shows that glucuronidation of polyphenols
first occurs in the enterocytes before further conjugation in
the liver(16).
Polyphenols and their derivatives are eliminated chiefly in
urine and bile. Polyphenols are secreted via the biliary route
into the duodenum, where they are subjected to the action of
bacterial enzymes, especially b-glucuronidase, in the distal
segments of the intestine, after which they may be reabsorbed.
This enterohepatic recycling may lead to a prolonged presence
of polyphenols in the body(11).
The balance between sulfation and glucuronidation of poly-
phenols seems to be affected by species, sex, and food depri-
vation. Competitive inhibition of conjugation could also occur
in the presence of several polyphenols and xenobiotics in the
intestine(11). Dietary components are also known to influence
drug metabolism in humans. Diets containing cruciferous veg-
etables may induce glucuronidation while paracetamol and
oxacepam glucuronidation have been shown to be enhanced
in subjects fed with a diet containing cabbage and Brussels
sprouts(15). Other factors that may affect drug glucuronidation
in humans are age, cigarette smoking, disease, genetic factors
and ethnicity. Critchley et al. (2005) showed that Chinese sub-
jects excreted 6 % more sulfate and 5 % less glucuronide
than Caucasian subjects after oral ingestion of paracetamol(17).
It is not yet known, however, whether these differences are
purely genetic or due to lifelong dietary habits modifying
the enzymic pathways that affect polyphenol metabolism
and excretion.
In many countries, one of the main ways of consuming
cocoa is in preparations containing cocoa (called cocoa
powder). Spain is the country with the highest consumption
of cocoa powder in the world (1·7 kg/person per year), this
product being present in more than 80 % of Spanish house-
holds with children and it represents the main source of flavo-
noids in the young population (children and teenagers , 15
years). In fact, cocoa powder consumption (especially con-
sumed during breakfast) with milk represents about 50 % of
the daily total flavonoid intake. Other countries with similar
consumption of such products are Norway, Sweden, France,
Brazil, Austria and Australia(18). Thus, the present study
aims to observe the effect of milk on urine excretion of
flavonoid metabolites after the intake of a standard portion
of cocoa powder, a polyphenol-rich food.
Material and methods
Materials
Reagents were obtained from the following sources: methanol
and acetonitrile (HPLC grade) from Scharlau (Barcelona,
Spain); o-phosphoric acid from Panreac (Barcelona, Spain);
formic acid from Sigma (Steinheim, Germany). Standards
were obtained as follows: (2 )-epicatechin ((2 )-Ec) from
Sigma (St Louis, MO, USA); taxifolin from Extrasynthese
(Genay, France); creatinine from Fluka (Seelze, Germany).
All the chemicals used were of analytical or chromato-
graphic grade. The water was purified in a Milli-Q water
purification system (Millipore, Molsheim, France). Working
standard solutions were filtered with Waters 4 mm polytetra-
fluoroethylene (PTFE) 0·45mm (Waters, Milford, MA, USA)
filters before being injected into the column and the extraction
cartridges were Waters OasisTM hydrophilic–lipophilic-
balanced (HLB) 3 cc (60 mg).
Subjects and study design
Twenty-one non-smoking healthy volunteers (nine women
and twelve men) with an average age of 25·7 (SD 6·9;
range 18–50) years and with an average BMI of 21·59 (SD
2·1; range 19·1–27·7) kg/m2 were selected. None of them
reported any history of heart disease, homeostatic disorders
or other medical conditions. None of the subjects was
receiving any medication or taking any vitamin supplements.
The Institutional Review Board of the Hospital Clinic in Bar-
celona approved the study protocol and all the volunteers
gave informed, written consent before they were included
in the trial.
The study was an open, prospective, randomised cross-over
clinical trial. Participants were instructed to abstain from alco-
holic beverages and any polyphenol-rich foods for at least 48 h
before the study as well as during the day of the study. The
day before the study, all the participants were given two
menus and a list showing permitted and forbidden foods
in order to help them follow the polyphenol-free diet correctly.
The subjects fasted for at least 8 h before consuming the test
meals.
On three different days (with a 1-week interval between
them), using a cross-over experimental design, the twenty-
one subjects received the three different meals in a random
order: (1) cocoa beverage containing 40 g cocoa powder
(Nutrexpa, Barcelona, Spain) and 250 ml whole milk (CC–
M); (2) cocoa beverage containing 40 g of the same cocoa
powder (Nutrexpa) and 250 ml water (CC–W); (3) 250 ml
whole milk as a control. In order to avoid differences in
the rate of stomach emptying (which in turn would
influence absorption kinetics) sugar was added to balance
energy content, thus making the three test meals isoen-
ergetic. Test meals were prepared on each day of the
study following a standardised procedure. The CC–M and
CC–W macronutrient composition (in 250 ml) was: carbo-
hydrates, 30·75 and 58·4 g; fat, 10·91 and 2·16 g; protein,
13·54 and 5·64 g; energy, 1152 kJ (275·35 kcal) and 1158 kJ
(276·6 kcal) respectively. Flavonoid composition was as foll-
ows: (2 )-Ec, 28·2 mg; procyanidin B2, 25·5 mg; (þ)-cate-
chin, 8·4 mg; flavonols, 2 mg. The flavonols included
isoquercitrin, quercetin, quercetin-3-glucoside and quercetin-
3-arabinoside. Phenolic compounds were not detected in the
milk used.
Urine samples were obtained before consumption and
during the 0–6, 6–12 and 12–24 h periods after test meal con-
sumption. The volunteers remained in the clinical ward for
over 6 h to avoid the possibility of transgressing the proscribed
diet in the first study period. For the remaining 18 h, all
the volunteers followed a standardised polyphenol-free diet
(as they had done the day before the study).

















Urine metabolite content determination by liquid
chromatography–mass-spectrometry/mass spectrometry
analysis
After collection and storage of urine samples, they were trea-
ted and analysed as described in a previous study(19) with
some modifications. Briefly, 1 ml homogenised urine was sub-
jected to a solid-phase extraction procedure (SPE) with a
Waters OasisTM hydrophilic–lipophilic-balanced (HLB)
ninety-six-well SPE plate (30 mg), preconditioned with 1 ml
methanol and equilibrated with 1 ml of 1·5 M-formic acid.
The plate was washed with 1 ml of 1·5 M-formic acid and
1 ml of 5 % methanol in water. The analytes were collected
in a ninety-six-well collection plate by elution with 1·5 ml
methanol containing formic acid (1 ml/l). The eluate was
evaporated to dryness using a Techne sample concentrator
(Duxford, Cambs, UK) at 308C under an N2 stream. The
residue was reconstituted with a sample of 100ml taxifolin
dissolved in mobile phase as additional internal standard
to assess the performance of the mass spectrometer. It was
then vortexed briefly and left in a refrigerated autosampler
for HPLC–MS/MS analysis.
A triple quadrupole mass spectrometer was used for the
analysis and quantification of (2 )-Ec metabolites. Liquid
chromatography analyses were performed using a Perkin
Elmer series 200 (Norwalk, CT, USA) with a quaternary
pump. An API 3000 triple quadrupole mass spectrometer
(Perkin-Elmer Sciex, Concord, ON, Canada) equipped with
a Turboionspray source in a negative ion mode was used to
obtain the MS and MS/MS data. The column that was selected
for the analyses was a Luna C18 column (50 £ 2 mm internal
diameter, 5mm) (Phenomenex, Torrance, CA, USA).
The MS/MS analyses were rigorous and described in detail
in a previous study(19). Briefing, a urine sample from 6 h after
the cocoa beverage intake was investigated using liquid chro-
matography–MS/MS in multiple-reaction monitoring mode to
check the traces of all cocoa (2 )-Ec metabolites described in
the literature; (2 )-Ec (m/z 289/245), O-methyl-epicatechin
(m/z 303/289), (2)-Ec-glucuronide (m/z 465/289), O-methyl-
(2 )-Ec-glucuronide (m/z 479/289), (2)-Ec-sulfate (m/z 369/
289), sulfated-O-methyl-epicatechin (m/z 383/289), sulfate-
epicatechin-glucuronide (m/z 545/289) and sulfate-O-methy-
l-epicatechin-glucuronide (m/z 559/289), to identify the
metabolites and to establish their retention time. Once
identified, the urine metabolites were confirmed in a second
experiment, a product-ion scan, which only confirmed the sul-
fate (m/z 369/289) and glucuronide (m/z 465/289) metabolites.
Statistical analysis
All statistical analysis was performed using SPSS for Windows
software, version 11·5 (SPSS Japan Inc., Tokyo, Japan). A two-
tailed paired t test was used to compare (2 )-Ec metabolite
concentrations excreted during the 0–6, 6–12 and 12–24 h
periods after the intake of the test meals. Differences between
the three meals were also studied by analysis of covariance
using general linear models; baseline values and sex were used
as covariates. Significance was recognised at P,0·05 and the
variables are presented as arithmetic means and standard
deviations.
Results
(2 )-Ec metabolites excreted are expressed per g creatinine
excreted in urine instead of per litre (volume) of urine, i.e.
mg (2 )-Ec/g creatinine. We used the classical Jaffe´ alkaline
picrate method to determine the amount of creatinine in the
urine(20).
Quantitative analysis of (2)-epicatechin metabolite excretion
in urine
Four (2 )-Ec metabolites were detected in the urine samples
collected during the 0–6, 6–12 and 12–24 h periods after
the ingestion of the two cocoa beverages (CC–W and CC–
M). One (2)-Ec-glucuronide ((2 )-Ec-G) and three (2 )-Ec-
sulfates ((2 )-Ec-S) were identified and confirmed in the
urine samples (Table 1). The following names were assigned
to the three (2)-Ec-S)detected: (2 )-Ec-S1, (2 )-Ec-S2 and
(2 )-Ec-S3, where the numbers 1, 2 and 3 correspond to the
order of appearance in the liquid chromatography analysis,
number 1 being the most polar sulfate and number 3 the
least. Both before consumption of the test meals and after con-
sumption of the control meal (milk, control), no (2)-Ec urine
metabolites were detected in any of the subjects.
After statistical analysis of the data applying a significance
test (paired t test) for each treatment (CC–M and CC–W) and
excretion time, we observed that there were no significant
Table 1. (2 )-Epicatechin ((2 )-Ec) metabolite concentrations in the three urine excretion periods after intake of the two cocoa beverages*
(Mean values and standard deviations)
Metabolite concentration (mg (2 )-Ec/g creatinine)
Beverage Time (h) Ec-S1 Ec-S2 Ec-S3 SEc-S1, Ec-S2, Ec-S3 Ec-G Total SD
CC–M 0–6 30·86 10·61 72·45 113·92 112·79 226·7 195·68
6–12 15·74 128·47 9·86 154·07 58·9 207·41 132·03
12–24 5·04 48·01 ND 50·65 9·25 58·92 34·76
CC–W 0–6 48·83 29·61 5·07 83·52 194·95 278·47 252·47
6–12 18·57 195·29 1·30 215·16 64·20 272·60 215·33
12–24 2·74 32·30 ND 37·10 9·41 44·45 29·18
Ec-S1, epicatechin-sulfate 1; Ec-S2, epicatechin-sulfate 2, Ec-S3, epicatechin-sulfate 3; SEc-S1, Ec-S2, Ec-S3, sum of the three detected sulfates; Ec-G, epicate-
chin-glucuronide; Total, sum of the four excreted metabolites; CC–M, 40 g cocoa powder dissolved in 250 ml whole milk; CC–W, 40 g cocoa powder dissolved
in 250 ml water; ND, not detected.
* For details of subjects and procedures, see Materials and methods.

















differences in total metabolite excretion (considering the sum
of all metabolites) between the two treatments for any of the
time periods (P,0·05; all). However, when we considered
the metabolite profile (the qualitative data) as shown in
Fig. 1, we observed that even though milk does not modify
the total excretion of (2 )-Ec metabolites, it modifies the
(2 )-Ec metabolite excretion profile. Although the maximum
concentration of total metabolites excreted was observed
during the 0–6 h period after intake of both CC–W and
CC–M, statistically there were no differences between total
excretion during the 0–6 h and during the 6–12 h periods.
Thus, after consumption of the cocoa beverage, with milk or
with water, the maximum concentration of metabolites
excreted in urine occurs between 0 and 12 h after intake.
During the following 12–24 h period, the metabolite concen-
trations returned to their base levels.
The most interesting finding, however, did not concern the
total metabolite excretion, but rather the excreted metabolite
profile. Up until 6 h after CC–W intake, (2 )-Ec-G is the
main metabolite observed (Fig. 1 (a)), followed by (2 )-Ec-
S1 and (2 )-Ec-S2. In this case, the sum of the sulfates does
not reach half of the excreted (2 )-Ec-G concentration. In con-
trast, although up until 6 h after the intake of the cocoa with
milk beverage (CC–M), (2 )-Ec-G is still the main excreted
metabolite (see Fig. 1 (b)), the sum of excreted sulfates has
the same concentration: 6 h after the intake of the cocoa
with milk beverage, the same quantity of glucuronide and sul-
fate metabolites had been excreted.
Another difference in metabolite excretion after the meals
is that at 0–6 h after CC–M intake, (2 )-Ec-S3 was the
main sulfate, whereas it was barely present in the urine
samples corresponding to CC–W after the same time period.
During the period 6–12 h after the ingestion of both cocoa
meals, the main excreted metabolite was (2 )-Ec-S2, followed
by (2 )-Ec-G, although the latter at much lower concen-
trations. Therefore, there is a change in the excretion profile:
while from 0–6 h after consumption the main excreted
metabolite was (2)-Ec-G, 6–12 h after intake the main
metabolite was (2 )-Ec-S2. During both the 6–12 h period
and the 0–6 h period, urine samples corresponding to the
CC–M treatment contained the (2 )-Ec-S3 metabolite, which
was not detected in the urine samples corresponding to the
CC–W treatment during the same periods.
For both treatments, after 24 h, (2 )-Ec-S2 is still the main
metabolite (despite low concentrations, , 50mg/l) followed
by small traces of (2 )-Ec-G (,15mg/l).
Discussion
The pharmacokinetics of (2)-Ec and its metabolites in
human plasma after consumption of the same cocoa beve-
rages have been studied in a previous study where we did
not find significant differences between the amounts of
(2 )-Ec metabolites found in plasma 2 h after CC–M and
CC–W consumption(18). However, the present study reports
the urinary excretion of (2 )-Ec and its metabolites after
CC–M and CC–W consumption during periods 0–6, 6–12
and 12–24 h after consumption in the human subjects.
While the total amount of (2)-Ec and its metabolites
excreted by urine did not change after CC–M and CC–W
Fig. 1. Graphic representations of (2)-epicatechin ((2 )-Ec) metabolite concentrations (mg (2 )-Ec/g creatinine) during the three urine excretion periods after intake
of the two cocoa beverages: 40 g cocoa powder dissolved in 250 ml whole milk (a) and 40 g cocoa powder dissolved in 250 ml water (b). Values are means, with
standard deviations represented by vertical bars. ( ), Epicatechin-sulfate 1; ( ), epicatechin-sulfate 2; ( ), epicatechin-sulfate 3; ( ), sum of the three detected
sulfates; ( ), epicatechin-glucuronide; ( ), sum of the four excreted metabolites.

















consumption, the metabolite profile differed. We observed
that milk affects flavonoid metabolism pathways, increasing
sulfation compared with glucuronidation in the first 6 h
excretion period.
Other studies have observed that matrices may affect
excretion of polyphenols. Donovan et al. (2002) reported
that 20 % more catechin metabolites were excreted in urine
over a period of 8 h after the intake of red wine compared
with dealcoholised red wine, indicating that ethanol enhances
the rate of catechin elimination. However, alcohol did not sig-
nificantly affect the percentage of the individual conjugate
forms(21). Urine volume was increased by 17 % after consum-
ing wine with ethanol, suggesting that this increase is due to a
diuretic effect(7). On the other hand, Goldberg et al. (2003)
investigated the total urinary excretion of resveratrol, catechin
and quercetin after consumption in three different matrices
(grape juice, white wine and vegetable homogenate) and
showed that 24 h resveratrol urinary excretion after oral con-
sumption did not show any matrix effect, while catechin
excretion varied with the matrix (being higher when consumed
with wine). No changes were observed in the excreted meta-
bolite profiles due to the matrix effect(10), because they also
determined polyphenol excretion after urine enzymic treat-
ment with b-glucuronidase and sulfatase, and the individual
metabolite forms were thus lost.
Polyphenols can interact with proteins that might decrease
the bioavailability of these antioxidants. The interaction,
resulting in protein–polyphenol complexes, can be either
reversible or irreversible depending on pH, temperature, type
of protein and flavonoid concentrations. The fate of these
complexes in the gastrointestinal tract is not known(21). Sera-
fini et al. (1996) found that the addition of milk to black tea
negates the increased antioxidant potential observed when
tea is consumed without milk, explaining that the mitigation
of this effect by milk is thought to be due to the interaction
of tea polyphenols with milk proteins(8). However, Arts et al.
(2002) showed no relevant effect of proteins on the bioavail-
ability or on the antioxidant capacity of tea polyphenols(22)
and Shroeter et al. (2003) described that the presence of
milk in cocoa products does not counteract the absorption
and biological activity of monomeric flavanols from cocoa
products, nor does it affect plasma antioxidant capacity(23).
Drug metabolism is categorised in two phases; phase I for
chemical modification such as oxidation, reduction and
hydroxylation, and phase II for conjugations such as glucuro-
nidation, methylation and sulfation at specific functional
groups. The ultimate goal of hepatic metabolism is detoxifica-
tion and the conversion of xenobiotics into more soluble or
hydrophilic forms to facilitate excretion(14). The present
study provides no information on the mechanisms involved
or their efficiency when these compounds enter the enterocyte
for hydrolysation and later enter the hepatocyte to be conju-
gated and reconjugated.
Antioxidant activity of polyphenols is directly related to their
chemical structure, thus the antioxidant capacity of their
metabolites would be very different. Several studies of the
structure–activity relationship on radical-scavenging activity
of flavonol-type flavonoids revealed that the o-dihydroxyl
structure in the B ring is mostly responsible for their radical-
scavenging activity. Yamamoto et al. (1999) described an
increasing order of inhibition of 2,20-azobis (2-amidinopropane)
dihydrochloride-induced lipid peroxidation in LDL by diff-
erent quercetin metabolites: Q40G , isorhamnetin , Q3G ,
rhamnetin ¼ Q7G ¼ quercetin, confirming that the o-dihy-
droxyl structure in the B ring is mostly responsible for scaven-
ging free radicals involved in lipid peroxidation of LDL.
This implies that the capacity of free-radical scavenging of
quercetin is significantly lowered by the introduction of a substi-
tuents group into the o-dihydroxyl structure in the B ring(24).
Natsume et al. (2004) described that the (2)-Ec-G metabolites
have different antioxidant activities; they described that
concentrations of 42·9mM-Ec–7-glucuronide and Ec-3-glucur-
onide caused 61 and 20 % inhibition of thiobarbituric acid-
reactive substance production; thus the position of the
conjugated position can modify the antioxidant capacity of the
metabolites(25).
It is evident, however, that (2)-Ec is subjected to glucuro-
nidation and sulfation. The enzymes involved in the synthesis
of these metabolites are glucuronosyltransferase and sulfo-
transferase, which are also found in the human intestine.
It is, therefore, feasible that all the (2)-Ec metabolites that
appear in plasma are the result of conversions that occur in
the lumen of the small intestine. Once these metabolites
have been produced in the small intestine, they pass into the
portal vein and are further converted and reconjugated because
human hepatocytes contain glucuronyl-, sulfo- and methyl-
transferases as well as b-glucuronidase activity(26). Ex vivo
incubation of quercetin-3-glucuronide with human hepG2 he-
patonoma cells results in cleavage of the glucuronide moiety
and the formation of quercetin-30-sulfate(27). Milk does not
have any effect on the absorption of (2)-Ec in cocoa
powder, because 2 h after cocoa consumption, the only meta-
bolite found was (2)-Ec-G. However, differences were
observed in the metabolite profile of urine; milk may therefore
alter some enzymic pathways. Further investigation is necess-
ary to understand possible milk interactions in phase II drug
metabolism clearly.
The present study shows for the first time that the matrix
does affect the metabolic phenolic profile. The present study
provides detailed quantitative information regarding concen-
trations of glucuronyl- and sulfo-conjugates, (2 )-Ec meta-
bolites, in the urine of human subjects after ingestion of a
standard portion of cocoa powder dissolved in water or
milk. These data should enable better and more relevant
studies of the bioactivity and role of dietary flavanols in
their possible interaction with other food or food com-
ponents. The excreted metabolite profile is affected when
the cocoa powder is consumed with milk, which seems to
induce the excretion of sulfates before glucuronides. The posi-
tion of sulfation is also affected. However, further studies are
necessary to elucidate the possible biological consequences
of these differences.
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